The FDA approved the Tecnis PureSee IOL, an extended depth of focus IOL for cataract surgery, according to a press release from Johnson & Johnson.
A previous analysis of the lens found that 97% of patients reported “no very bothersome visual disturbances,” with 97% of patients reporting that they would recommend the IOL to friends and family.
According to the release, this is the first FDAapproved extended depth of focus IOL with no warning on loss of contrast sensitivity. In addition, it reduces the impact of presbyopia and reliance on glasses after surgery. The IOL provides “excellent